Gilead Acquires Tubulis to Enhance Oncology Pipeline with Top Antibody-Drug Conjugates
Gilead Sciences has agreed to buy German biotech Tubulis GmbH. The deal brings clinical-stage antibody-drug conjugates and platform technologies into Gilead’s oncology portfolio.
Deal details and timeline
Gilead will pay $3.15 billion upfront in cash for all outstanding Tubulis equity. The purchase is on a cash-free, debt-free basis and is subject to customary adjustments.
There are up to $1.85 billion in contingent milestone payments. The transaction is expected to close in the second quarter of 2026. Closing depends on regulatory filings and usual closing conditions.
How the acquisition will be financed
Gilead plans to fund the purchase using cash on hand and senior unsecured notes. The company announced this financing approach alongside the acquisition.
Programs joining Gilead
Tubulis’ lead candidate is TUB-040. It is a NaPi2b-directed topoisomerase-I inhibitor ADC in Phase 1b/2 trials.
TUB-040 is being evaluated for platinum-resistant ovarian cancer and non-small cell lung cancer. The company will also add TUB-030, a 5T4-targeted ADC with encouraging initial clinical data.
Scientific rationale
Tubulis develops next-generation antibody-drug conjugates designed for selective payload delivery. Their platforms aim to improve tumor targeting and broaden payload diversity.
Preclinical data showed durable on-tumor delivery and sustained anti-tumor activity. Early clinical proof-of-concept was observed in platinum-resistant ovarian cancer.
Operational integration
After closing, Tubulis will operate as a dedicated ADC research organization within Gilead. The Munich site will serve as a hub for ADC innovation and development.
Gilead and Tubulis already had a two-year collaboration. That partnership informed Gilead’s decision to move forward with the acquisition.
Advisors and legal counsel
- Gilead financial advisors: Centerview Partners LLC and Allen & Company LLC.
- Tubulis exclusive financial advisor: J.P. Morgan Securities LLC.
- Gilead legal counsel: Covington & Burling LLP, Arnold & Porter LLP, and Venable LLP.
- Tubulis legal counsel: Goodwin Procter LLP and CMS Hasche Sigle.
Investor briefing and corporate context
Gilead scheduled an investor call for April 7 at 1:30 p.m. PT to discuss this deal and recent transactions. Details were made available through the company’s investor relations channels.
The acquisition expands Gilead’s oncology pipeline and complements its work with Kite Oncology. It aligns with Gilead’s broader strategy to enhance cancer research and development.
Regulatory and risk considerations
The transaction announcement included standard forward-looking disclaimers. Risks include regulatory approvals, integration challenges, and clinical development outcomes.
Gilead emphasized that expected benefits depend on successful development and commercialization of the acquired assets.
For more details and official materials, visit Filmogaz.com. The information in this report reflects the companies’ public statements and filings.
